Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMN7QB8)

Drug Name

PMID24915291C31 Drug Info

Synonyms

GTPL8148; BDBM50020471

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 71519693
CAS Number: CAS 1431727-00-2
TTD Drug ID: DMN7QB8

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Patented Agent(s)

Investigative Drug(s)

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Tyrosine-protein kinase Tec (PSCTK4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pyrazolo[4,3-c]pyridine derivative 2	DMCDFLQ	N. A.	N. A.	Patented	[2]
PMID24915291C38	DMBXT9J	Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------

Drug(s) Targeting Tyrosine-protein kinase BTK (ATK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibrutinib	DMHZCPO	Mantle cell lymphoma	2A85.5	Approved	[3]
Acalabrutinib	DM7GCVW	leukaemia	2A60-2B33	Approved	[4]
Zanubrutinib	DMJWRQP	Mantle cell lymphoma	2A85.5	Approved	[5]
Pirtobrutinib	DMRG1X3	Non-hodgkin lymphoma	2B33.5	Approved	[6]
GDC-0853	DMBEL3Q	Multiple sclerosis	8A40	Phase 3	[7]
ICP-022	DMU72KL	Chronic lymphocytic leukaemia	2A82.0	Phase 3	[8]
Tolebrutinib	DML19V6	Multiple sclerosis	8A40	Phase 3	[9]
CC-292	DMJR9H0	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[10]
BMS-986142	DMZB8AJ	Rheumatoid arthritis	FA20	Phase 2	[7]
LOU064	DME8O5K	Chronic idiopathic urticaria	EB00.1	Phase 2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Tyrosine-protein kinase TXK (TXK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID24915291C38	DMBXT9J	Discovery agent	N.A.	Investigative	[1]
PMID17600705C23	DMJFOGW	Discovery agent	N.A.	Investigative	[12]
------------------------------------------------------------------------------------

Drug(s) Targeting B lymphocyte kinase (BLK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pyrazolo[4,3-c]pyridine derivative 2	DMCDFLQ	N. A.	N. A.	Patented	[2]
PMID24915291C38	DMBXT9J	Discovery agent	N.A.	Investigative	[1]
PMID15546730C2	DMOPUIH	Discovery agent	N.A.	Investigative	[13]
------------------------------------------------------------------------------------

Drug(s) Targeting Tyrosine-protein kinase BMX (BMX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID24915291C38	DMBXT9J	Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B lymphocyte kinase (BLK)	TTNDSC3	BLK_HUMAN	Inhibitor	[1]
Tyrosine-protein kinase BMX (BMX)	TTN2I9E	BMX_HUMAN	Inhibitor	[1]
Tyrosine-protein kinase BTK (ATK)	TTGM6VW	BTK_HUMAN	Inhibitor	[1]
Tyrosine-protein kinase Tec (PSCTK4)	TT1ZV49	TEC_HUMAN	Inhibitor	[1]
Tyrosine-protein kinase TXK (TXK)	TT8M1DP	TXK_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
2	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1948).
4	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
6	Targeting BTK in CLL: Beyond Ibrutinib. Curr Hematol Malig Rep. 2019 Jun;14(3):197-205.
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8	Clinical pipeline report, company report or official report of InnoCare Pharma.
9	Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021 Sep;20(9):729-738.
10	Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013 Aug;346(2):219-28.
11	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
12	N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4363-8.
13	Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6.